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• Apoptosis (from Greek - 'falling off) is a term coined 
by Kerr, Wyllie and Currie in 1972 to describe a form of cell 
death associated with peculiar morphological changes (1). They 
contrasted apoptosis with necrosis, in which large numbers of 
cells undergo destruction and elicit a regional inflammatory 
response. In contrast, in apoptosis individual cells die and are 
being removed quickly, without inflammation, making their 
demise often difficult to detect. The initial concept of apoptosis 
was exclusively related to a morphological phenomenon. 
Interest surged in the mid-eighties, when it became clear that 
this morphologically defined form of cell death indicated a 
controlled form of cell demise associated with a large number 
of physiological and pathological processes. Apoptotis soon 
became recognized as playing a role in a multitude of eukaryote 
biological processes, such as steady-state cell turnover in heal- 
thy tissues, insect metamorphosis or the regulation of the cell 
number in the nervous and immune system. In addition, 
apoptosis occurred in pathological states, after growth factor 
or hormone deprivation, drug exposure, ionizing radiation, 
hypoxia, overexpression of various viral and cellular proteins, 
and in neoplasms (2). For processes of excess cell removal 
during growth and development the term programmed cell 
death (PCD) was introduced and it became associated and in 
fact loosly equated with apoptosis. Quite significantly, PCD 
can be inhibited by RNA transcription inhibitors like actino- 
mycin-D, or protein synthesis inhibitors like cycloheximide. 
Thus, PCD/apoptosis is an actively regulated process that re- 
quires the expression of various genes in order to take place. 
The third stage was set when the molecular mechanisms 
underlying controled cell death were unraveled in cell culture 
systems, simple organisms like C. elegans, or organotypic 
preparations (3,4). Both PCD and the various traumatic stimuli 
mentioned turned out to share similar molecular pathways, all 
leading to that final common pathway of morphological 
changes initially called apoptosis. Moreover, a surprising 
conservation of genes involved was found throughout eukary- 
otic cells, as well as in viruses. 
In the developing nervous system, PCD and apoptotic removal 
of excess neurons constitute an important mechanism respon- 
sible for the mature architectural configuration (5). It has been 
postulated that apoptosis is also the mode of neuronal de- 
struction in human neurodegenerative diseases (3,6). Although 
circumstantial evidence may seem to support this view, in this 
Dance Round we will try to demonstrate that up to now no- 
body has unequivocally demonstrated apoptosis in the ner- 
vous system of patients who died with neurodegenerative dis- 
eases. No one has been able to fulfill the strict morphological 
and molecular criteria for apoptosis in human postmortem 
brain. But absence of proof is not proof of absence: rather than 
due to non-existence, the difficulties of demonstrating apoptosis 
may be a result of the peculiar characteristics of the process. 
• Apoptosis: morphological criteria and molecular 
mechanisms 





phological alterations. In the earliest phase, cells undergo ag- 
gregation of nuclear chromatin into large, compact masses 
localized at the membrane and resulting in an irregularly con- 
voluted nuclear surface. Somewhat later the nucleus becomes 
indented and ultimately fragmented. This process is best ob- 
served by transmission electron microscopy but may be revealed 
in light microscopy as pyknosis and karyorrhexis, respectively. 
At the same time cytoplasmic condensation takes place. Cells 
shrink, organelles crowd, but do not lose their integrity, and 
become sequestered within membraneous envelopes that ini- 
tially form blebs on the cell surface, soon to be detached as 
apoptotic bodies. These bodies, as well as the remains of the 
original cell, become engulfed in tissue resident cells or in 
macrophages, without inflammatory response elicited. 
Characteristically, it may take only a few hours before a cell 
undergoing apoptosis is completely removed, although intrac- 
ellular apoptotic bodies that have been scavenged may be de- 
tectable for more than 12 hours (2). Fig. 1 shows apoptotic cells 
in a classical model, the rat prostate 3 days after castration. 
Of the various molecular events associated with apoptosis, some 
important ones are related to DNA degradation. In rodent thy- 
mocytes undergoing apoptosis after treatment with glucocor- 
ticoids, a characteristic "DNA-laddering" can be found. Elec- 
trophoretic separation of extracted DNA on agarose gels reve- 
als fragments that are multiples of-180 bp. This periodicity 
is due to multiple single-strand nicks in the internucleosomal 
linker region and follows the initial generation of much larger 
fragments associated with the unfolding of chromatin loop 
domains (7). The endonucleases considered to be responsible 
for internucleosomal cleavage include DNase I, DNase II, and 
NUC 18, an 18 kD DNase isolated from glucocorticoid-treated 
thymocyte nuclei (7). Methods have been developed that use 
in situ end-labeling (ISEL) to demonstrate in individual cells 
the existence of DNA breaks. In situ nick translantion (ISNT) 
employs DNA polymerase I, while TdT-mediated dUTP nick- 




Figure 1.   Cells undergoing apoptosis in a classical model, the rat prostate 3 days after castration. Arrows point to 
apoptotic cells. Hematoxylin and eosin. x 40. 
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Internucleosomal cleavage, chromatin condensation and mem- 
brane redistribution are the final steps in an extensive molecular 
pathway that involves an intricate machinery of apoptosis in- 
ducing and inhibiting factors. The most extensively studied 
proteins participating in this machinery are proteins from the 
bcl-2 family. Bcl-2 is a proto-oncogen that was originally iden- 
tified in B cell lymphomas at a chromosomal t(14;18) break- 
point that juxtaposes the chromosome 18 bcl-2 gene to the 
immunoglobulin heavy chain locus on chromosome 14. Thus, 
a bcl-2-lGR fusion gene is created that is overexpressed in 
lymphoid tissue and results in a polyclonal expansion of small 
resting B cells that fail to die (11-13). These findings implied 
that bcl-2 is an apoptosis-inhibiting gene. Consistent with this 
notion, bcl-2 showed a surprising 23% homology to a C. 
elegans death-protecting gene, ced-9, and could in fact rescue 
ced-9 mutants from untimely apoptotic death (14). A protecti- 
ve role for the bcl-2 protein in apoptosis has now been demon- 
strated in a variety of experimental systems, including cell 
death induced by nerve growth factor (NGF) withdrawal, 
gamma irradiation, and cancer chemotherapeutics (15). In 
addition, the protein plays a physiological role in B-cell and 
T-cell development. As demonstrated by immunohistochemis- 
try, bcl-2 is expressed in a wide variety of tissues, including 
germinal centers of lymphoid follicles, precursor cells of 
hematopoietic lines, various glandular and epithelial tissues, 
particularly hormone-dependent forms, and neurons in the 
temporal cortex (16). No immunorectivity was found in glial 
cells. 
Various bcl-2 -related genes have been identified that may also 
be involved in apoptosis regulation. These genes include bcl-x 
(with its two splice variants, a large one, bcl-xp and a small one, 
bcl-x), MCL1, and box. This group of genes shares at least two 
homologous domains, called BH1 and BH2 (17). Like bcl-2, the 
box protein is widely distributed in various cell types. In the 
central nervous system, bax immunorectivity was localized in 
spinal motor neurons (particularly if they showed degenerative 
features), dorsal ganglion sensory neurons, brainstem motor 
neurons and reticular neurons, Purkinje cells, and cortical large 
and medium sized neurons (18). Again, bax immunoreactivity 
was absent in glial cells and Schwann cells. It was noted that 
bax and bcl-2 immunoreactivity do not to overlap completely 
(18). This finding is interesting as bax and bcl-2 seem to 
excercize opposing roles in apoptosis regulation. Whereas bcl- 
2 prevents cell death, bax expression is associated with the 
occurrence of apoptosis. The two proteins are able to form 
homo- or heterodimers, a proces dependent upon the integrity 
of the BH1 and BH2 domains (19). The relative amounts ofbcl- 
2 and bax ultimately determine a cell's fate: with excess bcl-2, 
bcl-2 homodimers are formed predominantly, resulting in cell 
survival, whereas excess bax results in bax homodimers and 
apoptosis (20). The presence of bcl-2/bax heterodimers may 
thus represent a finely balanced intermediate state. 
A host of other gene products contribute to this system of checks 
and balances. Additional death promoting factors that have 
been identified include bcl-xt and interleukin converting en- 
zyme (ICE; homologous to the C. elegans death promoting 
gene ced-3). In contrast, bcl-x t and crrn A, a cowpox virus gene, 
prevent cell death. Bcl-xs and bcl-x t may form a complemen- 
tary pair similar to bcl-2 and bax. Moreover, extensive cross- 
talk seems possible. Both crmA and bcl-2 are able to repress 
ICE-dependent apoptosis in NGF-depleted cultured dorsal root 
ganglion cells, without additive or synergistic effects, suggest- 
ing a mode of action that involves one site (21). Currently, 
these complicated cellular networks that regulate apoptosis 
are only incompletely understood, but they may be crucial for 
our understanding of neurodegenerative diseases, 
•         Apoptosis in neurodegenerative disease 
Due to the non-inflammatory nature of neuronal falling off in 
neurodegenerative diseases, and the regional selectivity of 
degeneration in most of these diseases, apoptosis has been 
considered to be the mechanism of cell death in diseases such 
as Alzheimer disease (AD), Parkinson disease (PD), amyotro- 
phic lateral sclerosis (ALS), or Huntington disease (HD). How- 
ever, demonstrating apoptosis in human postmortem brain is 
difficult, primarily due to the kinetics of the process. An apopto- 
tic neuron is no longer visible after a few hours. In contrast, 
neurodegenerative diseases typically take many years to de- 
velop. Therefore, one can not expect to find more than a few 
neurons at most in a postmortem brain. Careful, exhausting 
quantitation of apoptotic neurons will be required to demon- 
strate the presence of apoptosis in affected brains unequivo- 
cally. 
Various studies have reported evidence of extensive ISEL/ 
TUNEL DNA-labeling in AD and HD (22-25), although dis- 
senting opinions can be found (10). One recent study reported 
finding up to 10 % of TUNEL labeling neurons locally in the 
striatum of HD brains (24). This finding could only be ex- 
plained by assuming that neurodegeneration in this disease is 
a process that is locally restricted in time, a notion clearly not 
in line with the clinical progress of the disease. Although the 
presence of ISEL/TUNEL-positive neurons as often consid- 
ered proof of apoptosis in the brains under consideration, the 
specificity of the method remains to be established, particu- 
larly in the postmortem central nervous system. In our expe- 
rience, TUNEL or ISEL in postmortem human central ner- 
vous system tissue labels far too many nuclei, probably through 
random DNA breaks (Fig. 2). This makes it difficult to distin- 
guish the few apoptotic neurons from the vast majority of neu- 
rons with necrotic, agonal, or postmortem DNA damage. 
TUNEL/ISEL labeling has been demonstrated quite convinc- 
ingly in ischemia models (26,27). 
  
105 




Figure 2.  TUN EL labeled neurons in the striatum oj'Huntington's disease patient, (a) Nuclear morphology suggestive of 
apoptosis. (b) Morphology suggestive of random DNA labeling. x400. 
  
Circumstantial evidence has been derived from studies in cul- 
tured cells. A role for PCD in human ALS was suggested by 
an apoptosis occurring in motoneurons deprived of trophic 
support (28), or in spinal neurons after chronic inhibition of 
superoxide dismutase (29). Apoptosis occurred in PC-12 pheo- 
chromocytoma cells treated with complex I inhibitors (30,31), 
and in ventral mesencephalic neuronal cultures after treatment 
with MPP+ (32), providing a link to PD. Ed-2 transfected 
and expressing PC-12 cells were protected against dopamine 
toxicity (33). Beta-amyloid may induce apoptosis in cultured 
cortical neurons (34). Although these results are suggestive to 
some extent of apoptosis playing a role, a direct extrapolation 
to the relevant human neurodegenerative disease is tenuous at 
best. 
If, either in human brains or animal models, alterations in the 
expression of proteins like bcl-2, bax, ICE or others will be 
demonstrated, that would constitute stronger evidence in favour 
of apoptosis. However, the most compelling evidence for a 
role of apoptosis would come from the elucidation of the func- 
tion of mutated genes or altered proteins. A recent study re- 
ported increased apoptosis in embryonic mice with a nullizy- 
gous knock out of the HD gene, suggesting, but not proving, a 
regulatory role for this gene in apoptosis (35). But currently 
the best case may be made for autosomal dominant spinal 
muscle atrophy (SMA). In line with an older study demonstra- 
ting apoptotic muscle fibers in a fulminant form of childhood 
SMA (36), a recent study found deletions in a gene with remar- 
kable homology to the baculoviral cp- and op-IAP anti-apopto- 
sis genes (37). Clearly, this now constitutes the best available 
evidence for any neurodegenerative disease of a role for 
apoptosis. Still, this mutation is not unambiguously establis- 
hed (38,39). 
In conclusion, the process of controled cell death, apoptosis, 
seems crucial to our understanding of normal cell physiology. 
In addition, it plays a role in pathologial cell death, and it has 
been proposed to take place in various human neurodege- 
nerative diseases. However, the currently available evidence 
seems insufficient to establish beyond doubt the existence of 
apoptosis in any neurodegenerative disease. Methodological 
considerations still complicate the search for apoptotic changes   
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in human postmortem material, and novel approaches are 
needed. One could argue that, on its own, the demonstration 
of apoptosis is not very relevant: the underlying molecular 
mechanisms need to be unraveled. But a demonstration of 
apoptosis would imply a restricted set of molecular pathways, 
focus further research efforts, and open up therapeutic strate- 
gies. It would embed research into these diseases into a far 
broader field of cellular biology: clearly a beneficial develop- 
ment for patients and their families. 
 
1. Kerr JFR, Wyllie AH, Currie AR. Apoptosis: a basic biolo- 
gical phenomenon with wide-ranging implications in tis- 
sue kinetics. Br J Cancer 1972; 26: 239-257 
2.     Wyllie AH, Kerr JFR, Currie AR. Cell death: the signifi- 
cance of apoptosis. IntRev Cytol 1980; 68: 251-306 
3.     Raff MC, Barres BA, Burne JF, Coles HS, Ishizaki Y, 
Jacobson MD. Programmed cell death and the control of 
cell survival: lessons from the nervous system. Science 
1993; 262: 695-700 
4.   Ellis RE, Yuan J, Horvitz HR. Mechanisms and func- 
tions of cell death. Anna Rev Cell Biol 1991; 7: 663-698 
5.      Oppenheim RW. Cell death during development of the 
        nervous system. Annu Rev Neurosci 1991; 14: 453-501 
6.     Heintz N. Cell death and the cell cycle: a relationship 
between transformation and neurodegeneration? Trends 
BiochemSci 1993; 18: 157-159 
7.     Peitsch MC, Mannherz HG, Tschopp J. The apoptosis 
endonucleases: cleaning up after cell death? Trends Cell 
Biol 1994; 4: 37-41 
8.     Wijsman JH, Jonker RR, Keijzer R, Van de Velde CJH, 
Cornelisse CJ, Van Dierendonck JH. A new method to 
detect apoptosis in paraffin sections: in situ end-labeling 
      of fragmented DNA. J Histochem Cytochem 1993; 41: 
7-12 
9.     Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification 
of programmed cell death in situ via specific labeling of 
nuclear DNA fragmentation. JCellBiol 1992; 119: 493- 
501 
10.   Migheli A, Cavalla P, Marino S, Schiffer D. A study of 
apoptosis in normal and pathologic nervous tissue after 
in situ end-labeling of DNA strand breaks. J Neuropathol 
ExpNeurol 1994; 53: 606-616 
11. Chen-Levy Z, Nourse J, Cleary ML. The bcl-2 candidate 
proto-oncogene product is a 24-kilodalton integral-mem- 
brane protein highly expressed in lymphoid cell lines and 
lymphomas carrying the t(14; 18) translocation. Mol Cell 
Biol 1989; 9: 701-710 
12. Graninger WB, Seto M, Boutain B, Goldman P, Korsmeyer 
SJ. Expression of Bcl-2 and Bcl-2-Ig fusion transcripts 
in normal and neoplastic cells. / Clin Invest 1987; 80: 
1512-1515 
13.   McDonnel TJ, Deane N, Platt FM, et al. Bcl-2 immuno- 
globulin transgenic mice demonstrate extended B cell 
survival and follicular lymphoproliferation. Cell 1989; 
57: 79-88. 
14. Hengartner MO, Horvitz HR. C. elegans cell survival gene 
ced-9 encodes a functional homolog of the mammalian 
proto-oncogene bcl-2. Cell 1994; 76: 665-676 
15.   Boise LH, Gottschalk AR, Quintans J, Thompson CB. 
Bcl-2 and Bcl-2-related proteins in apoptosis regulation. 
Curr Topics Microbiol Immunol 1995; 200: 107-121 
16.   Hockenbery DM, Zutter M, Hickey W, Nahm M. BCL2 
protein is topographically restricted in tissues character- 
ized by apoptotic cell death. Proc Nat I Acad Sci USA 
1991; 88: 6961-6965 
17.   Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 hetero- 
dimerizes in vivo with a conserved homolog, Bax, that 
accelerates programed cell death. Cell 1993; 74:609-619 
18.   Krajewski S, Krajewska M, Shabaik A, Miyashita T, Wag 
HG, Reed JC. Immunohistochemical determination of in 
vivo distribution of Bax, a dominant inhibitor of Bcl-2. 
AmJPathol 1994; 145: 1323-1336 
19.   Yin X-M, Zoltan ON, Korsmeyer SJ. BH1 and BH2 do- 
mains of Bcl-2 are required for inhibition of apoptosis 
and heterodimerization with Bax. Nature 1994; 369:321- 
323 
20. Oltvai ZN, Korsmeyer S J. Checkpoints of duelling dimers 
foil death wishes. Cell 1994; 79: 189-192 
21. Gagliardini V, Fernandez P-A, Lee RKK, et al. Preven- 
tion of vertebrate neuronal death by the crmA gene. Sci- 
ence 1994; 263: 826-828 
22.   Smale G, Nichols MR, Brady DR, Finch CE, Horton WE. 
Evidence for apoptotic cell death in Alzheimer's disease. 
ExpNeurol 1995; 133: 225-230 
  
107 
Biomed Rev 4,1995 
  
  
23.   Yoshiyama Y, Yamada T, Asanuma K, Asahi T. Apop- 
tosis related antigen, Le(Y) and nick-end labeling are 
positive in spinal motor neurons in amyotrophic lateral 
sclerosis. Acta Neuropathol (Berlin) 1994; 88: 207-211 
24.   Portera-Cailliau C, Hedreen JC, Price DL, Koliatsos VE. 
Evidence for apoptotic cell death in Huntington disease 
and excitotoxic animal models. / Neurosci 1995; 15: 
3775-3787  
25.   Dragunow M, Faull RLM, Lawlor P, et al. In situ evi- 
dence for DNA fragmentation in Huntington's disease 
striatum and Alzheimer's disease temporal lobes. Neuro 
Report 1995; 6: 1053-1057  
26.   Sei Y, Von Lubitz KJ, Basile AS, et al. Internucleosomal 
DNA fragmentation in gerbil hippocampus following 
forebrain ischemia. Neurosci Lett 1994; 171: 179-182 
27.   MacManus JP, Buchan AM, Hill IE, Rasquinha I, Preston 
E. Global ischemia can cause DNA fragmentation indica- 
tive of apoptosis in rat brain. Neurosci Lett 1993; 164: 
89-92 
28.   Milligan CE, Oppenheim RW, Schwartz LM. Motoneu- 
rons deprived of trophic support in vitro require new gene 
expression to undergo programmed cell death. / 
Neurobiol 1994; 25: 1005-1016 
29.   Rothstein JD, Bristol LA, Hosier B, Brown RH, Kuncl 
RW. Chronic inhibition of superoxide dismutase produces 
 
        apoptotic death of spinal neurons. Proc Natl Acad Sci 
USA 1994; 91: 4155-4159 
30.   Shahar A, Schupper H, Lustig S, Levin R, Friedmann A, 
    Fuchs P. Neuronal cell cultures as a model for assessing 
    neurotoxicity induced by encephalitic viruses. Neuroto- 
   
   Ecology 1992; 13: 171-177 
31.   Paulus W, Schwarz G, Werner A, et al. Impairment of 
retinal increment thresholds in Huntington's disease. Ann 
Neural 1993; 34: 574-578 
32.   Mochizuki H, Nakamura N, Nishi K, Mizuno Y. 
Apoptosis is induced by l-methyl-4-phenylpyridinium ion 
(MPP+) in ventral mesencephalic co-culture in rat. 
Neurosci Lett 1994;170:191-194. 
33.   Ziv I, Offen D, Barzilay A, Stein R, Melamed E. The 
proto-oncogene Bcl-2, a novel cellular protective mecha- 
nism against dopamine toxicity: possible implications for 
Parkinson'sdisease [abstract]. Neurology 1995; 45 (Suppl 
4): 279A 
34.   Loo DT, Copani A, Pike CJ, Whittemore ER, Walen- 
cewicz AJ, Cotman CW. Apoptosis is induced by beta- 
amyloid in cultured central nervous system neurons. Proc 
NatlAcadSci USA 1993; 90: 7951-7955 
3 5. Zeitlin S, Liu J-P, Chapman DL, Papaioannou VE, Efstratia- 
dis A. Increased apoptosis and early embryonic lethality 
in mice nullizygous for the Huntington's disease gene 
homologue. Nat Genet 1995; 11: 155-163 
36.   Fidzianska A, Goebel HH, Warlo I. Acute infantile spinal 
muscular atrophy. Muscle apoptosis as a proposed patho- 
genetic mechanism. Brain 1990; 113: 433-445 
37.   Roy N, Mahadevan MS, McLean M, et al. The gene for 
neuronal apoptosis inhibitory protein is partially deleted 
in individuals with spinal muscular atrophy. Cell 1995; 
80: 167-178 
38.   Lefebvre S, Buerglen L, Reboullet S, et al. Identification 
and characterization of a spinal muscular atrophy-deter- 
mining gene. Cell 1995; 80: 155-165 
39.   Lewin B. Genes for SMA: multum in parvo. Cell 1995; 
80: 1-5 
Received 2 November 1995 
Accepted 19 November 1995 
Address for correspondence: 
Dr Berry H.P.H. Kremer 
Departmeent of Neurology 
Academic Hospital 
Reinier Postlaan 4 
NL-6525 GC Nijmegen 
The Netherlands 
 Tel: 31 (24)3613394 
Fax: 31 (24) 3541122 
E-mail: h. kremer(a).czzoneu. azn. nl   
108 Timmers and Kremer 
Biomed Rev 4,1995 
